Setareh Akhavan; Jila Agah; Abbas Alipour
Volume 3, Issue 2 , May and June 2018, , Pages 59-63
Abstract
Aims: Ovarian cancer is the 4th cause of women’s mortality occurring due to cancer. Malignant germ cell tumors (GCTs) account for 5% of malignant ovarian tumors and 70% of ovarian tumors in women between the ages of 10-30 years old. The aim of the present study was to detect the frequency of malignant ...
Read More
Aims: Ovarian cancer is the 4th cause of women’s mortality occurring due to cancer. Malignant germ cell tumors (GCTs) account for 5% of malignant ovarian tumors and 70% of ovarian tumors in women between the ages of 10-30 years old. The aim of the present study was to detect the frequency of malignant ovarian germ cell tumor and distribution of demographic features in the most crowded gynecology oncology clinic.
Materials and Methods: This cohort descriptive-analytical study was conducted on cases with malignant ovarian tumor managed in Vali-Asr hospital, Tehran, Iran, from 2001 to 2018 (n=1540). The malignant germ cell tumors cases were extracted (n=128) and evaluated in point of epidemiologic and demographic data via the software SPSS 24.
Findings: 128 patients (8.3%) had GCTs. The average age was 23.88±7.85 years. 79.7% lived in the city, 76.6% had medium economic status and 53.6% had normal body mass index. Premature puberty was revealed in one person. Karyotype XY was detected in 5 persons. About 70.3% of the patients had no parity. In parous women, the highest percentage was related to a childbirth (55.0%). A history of infertility was detected at 6.1%. In 10 patients, the tumor was detected during pregnancy.
Conclusion: The highest frequency is related to the early young women with no considerable association with socioeconomic and weight status. It is possible that parity would be a protective factor for this tumor. In the case of adnexal mass during pregnancy, Malignant Germ cell tumors should be rolled out.
Sarah Khalifa; Maha E Muhammad; Rasha A. Khairy MD; Hala N Hosni; Ahmed M Abd E
Volume 3, Issue 1 , March and April 2018, , Pages 13-18
Abstract
Aims: Supporting evidences have been proposed that tumor initiating cells or cancer stem cells (CSCs) are principally sharing into tumor progress and relapse. Aldehyde dehydrogenase 1A1 (ALDH1A1), a stem cell marker, has currently been implicated in multiple human malignancies including ovarian carcinomas. ...
Read More
Aims: Supporting evidences have been proposed that tumor initiating cells or cancer stem cells (CSCs) are principally sharing into tumor progress and relapse. Aldehyde dehydrogenase 1A1 (ALDH1A1), a stem cell marker, has currently been implicated in multiple human malignancies including ovarian carcinomas. The aims of this study were to assess immunohistochemical (IHC) expression of ALDH1A1 in ovarian epithelial tumors, tracking stem cells during ovarian cancer development and its relation with the clinicopathological features of such tumors.
Materials and Methods: In this experimental study, 42 paraffin blocks of ovarian tumor cases were retrieved retrospectively from the department of pathology, faculty of medicine, Cairo University during January 2013 to January 2015. Ovarian tumor paraffin blocks included 14 benign cystadenomas 14 border line tumors and 14 carcinomas. IHC reactions were carried out by using ALDH1A1 monoclonal antibody. Cases were classified into two groups of low and high ALDH1A1 expression. The chi-squared test (χ2) was used and data analyzes by SPSS 22 software.
Findings: High ALDH1A1 expression was reported in 50.0% of benign cystadenomas, 50.0% of borderline tumors and 85.7% of ovarian carcinomas with significant positive association with ovarian carcinomas (p=0.025). In ovarian carcinomas, positive relationship was detected between high ALDHA1 expression and advancing tumor grades but it didn’t reach statistical significance (p=0.054), no any significant relations were detected between ALDH1A1 immunohistochemical expression and age of patients, the documented size, laterality, histologic types and FIGO stage in all tumors (p>0.05).
Conclusion: ALDH1A1 is a potential biomarker for detecting CSCs in ovarian carcinomas and a prognostic marker. Also, it may act as a target for future therapy.
Azar Ahmadzadeh; Nahid Shahbazian; Boshra Arkavazi
Volume 3, Issue 1 , March and April 2018, , Pages 19-22
Abstract
Aims Tumor markers are very applicable for examining differential diagnoses of adenosine masses. Increases in CA 19-9 have been reported in epithelial ovarian and endometrial tumors. Dermoid cysts are the most prevalent ovarian germ cell tumors. The aim of the present study was to examine Cancer Antigen ...
Read More
Aims Tumor markers are very applicable for examining differential diagnoses of adenosine masses. Increases in CA 19-9 have been reported in epithelial ovarian and endometrial tumors. Dermoid cysts are the most prevalent ovarian germ cell tumors. The aim of the present study was to examine Cancer Antigen 19-9 (CA 19-9) tumor marker in ovarian dermoid cysts.
Information and Methods This descriptive-analytic study was conducted using hospital records. By referring to archives of a Imam Khomeini Hospital, Ahwaz, Iran in 2016, the information of 73 patients with ovarian dermoid cysts were extracted that include their demographic information, cyst size, the location of involvement, the presence of symptoms of malignancy in sonography reports, and CA 19-9 serum levels prior to surgery. A pathologic report was used for the final mass diagnosis and determining the type of mass extracted from the patients’ bodies. Data were analyzed by SPSS 22 software using independent-sample t-test, chi-square test and Pearson correlation coefficient.
Findings All patients under study were diagnosed with dermoid cysts. In 9 patients (12.85%), symptoms of malignancy were reported in their sonography reports. The mean serum levels of CA 19-9 tumor marker was 46.13±11.65U/ml. There was a direct correlation between mass size and CA 19-9 serum concentrations (r=0.24). In 20% of the patients, the concentrations of CA 19-9 were normal.
Conclusion The CA 19-9 serum concentration is related to tumor size in cases of mature cystic teratoma. In most cases of unilateral mature cystic teratomas, the right ovary is mainly preferred to involve.